Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings and Inc.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Latest Biotechnology and Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings, Inc. Stock News

As of September 2, 2026, Intellia Therapeutics, Inc. had a $1.8 billion market capitalization, compared to the Biotechnology median of $288.9 million. Intellia Therapeutics, Inc.’s stock is up 39.9% in 2026, down 4.1% in the previous five trading days and up 11.93% in the past year.

Currently, Intellia Therapeutics, Inc. does not have a price-earnings ratio. Intellia Therapeutics, Inc.’s trailing 12-month revenue is $59.5 million with a -672.2% net profit margin. Year-over-year quarterly sales growth most recently was -45.8%. Analysts expect adjusted earnings to reach $-3.151 per share for the current fiscal year. Intellia Therapeutics, Inc. does not currently pay a dividend.

As of September 2, 2026, Ginkgo Bioworks Holdings, Inc. had a $473.4 million market cap, putting it in the 36th percentile of all stocks. Ginkgo Bioworks Holdings, Inc.’s stock is down 17.8% in 2026, down 5.9% in the previous five trading days and down 36.21% in the past year.

Currently, Ginkgo Bioworks Holdings, Inc. does not have a price-earnings ratio. Ginkgo Bioworks Holdings, Inc.’s trailing 12-month revenue is $132.4 million with a -219.6% net profit margin. Year-over-year quarterly sales growth most recently was -48.3%. Analysts expect adjusted earnings to reach $-3.200 per share for the current fiscal year. Ginkgo Bioworks Holdings, Inc. does not currently pay a dividend.

How We Compare Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings and Inc. Stock Value Grades

Company	Ticker	Value
Intellia Therapeutics, Inc.	NTLA	F
Ginkgo Bioworks Holdings, Inc.	DNA	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Intellia Therapeutics, Inc. has a Value Score of 9, which is Ultra Expensive. Ginkgo Bioworks Holdings, Inc. has a Value Score of 39, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings or Inc. is the better investment when it comes to value.

Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings and Inc. Growth Grades

Company	Ticker	Growth
Intellia Therapeutics, Inc.	NTLA	F
Ginkgo Bioworks Holdings, Inc.	DNA	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Intellia Therapeutics, Inc. has a Growth Score of 17, which is Very Weak. Ginkgo Bioworks Holdings, Inc. has a Growth Score of 14, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings or Inc. is the better investment when it comes to sustainable growth.

Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Intellia Therapeutics, Inc.	NTLA	D
Ginkgo Bioworks Holdings, Inc.	DNA	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Intellia Therapeutics, Inc. has a Earnings Estimate Score of 37, which is Negative. Ginkgo Bioworks Holdings, Inc. has a Earnings Estimate Score of 79, which is Positive.

The Earnings Estimate Revisions Grade Winner: Ginkgo Bioworks Holdings, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Ginkgo Bioworks Holdings, Inc. has a better Earnings Estimate Revisions Grade than Intellia Therapeutics, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Ginkgo Bioworks Holdings, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings and Inc. Grades

In addition to Growth, Estimate Revisions and Value, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings or Inc. Stock?

Overall, Intellia Therapeutics, Inc. stock has a Value Score of 9, Growth Score of 17 and Estimate Revisions Score of 37.

Ginkgo Bioworks Holdings, Inc. stock has a Value Score of 39, Growth Score of 14 and Estimate Revisions Score of 79.

Comparing Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.